Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stefanos A. Tsiftsoglou is active.

Publication


Featured researches published by Stefanos A. Tsiftsoglou.


Proceedings of the National Academy of Sciences of the United States of America | 2011

Structural basis for complement factor I control and its disease-associated sequence polymorphisms

Pietro Roversi; Steven G. Johnson; Joseph J. E. Caesar; F. McLean; Kirstin Leath; Stefanos A. Tsiftsoglou; Bryan Paul Morgan; Claire L. Harris; Robert B. Sim; Susan M. Lea

The complement system is a key component of innate and adaptive immune responses. Complement regulation is critical for prevention and control of disease. We have determined the crystal structure of the complement regulatory enzyme human factor I (fI). FI is in a proteolytically inactive form, demonstrating that it circulates in a zymogen-like state despite being fully processed to the mature sequence. Mapping of functional data from mutants of fI onto the structure suggests that this inactive form is maintained by the noncatalytic heavy-chain allosterically modulating activity of the light chain. Once the ternary complex of fI, a cofactor and a substrate is formed, the allosteric inhibition is released, and fI is oriented for cleavage. In addition to explaining how circulating fI is limited to cleaving only C3b/C4b, our model explains the molecular basis of disease-associated polymorphisms in fI and its cofactors.


Journal of Immunology | 2004

Human Complement Factor I Does Not Require Cofactors for Cleavage of Synthetic Substrates

Stefanos A. Tsiftsoglou; Robert B. Sim

Complement factor I (fI) plays a major role in the regulation of the complement system. It circulates in an active form and has very restricted specificity, cleaving only C3b or C4b in the presence of a cofactor such as factor H (fH), complement receptor type 1, membrane cofactor protein, or C4-binding protein. Using peptide-7-amino-4-methylcoumarin derivatives, we investigated the substrate specificity of fI. There is no previous report of synthetic substrate cleavage by fI, but five substrates were found in this study. A survey of 15 substrates and a range of inhibitors showed that fI has specificity similar to that of thrombin, but with much lower catalytic activity than that of thrombin. fI amidolytic activity has a pH optimum of 8.25, typical of serine proteases and is insensitive to ionic strength. This is in contrast to its proteolytic activity within the fI-C3b-fH reaction, in which the pH optimum for C3b cleavage is <5.5 and the reaction rate is highly dependent on ionic strength. The rate of cleavage of tripeptide 7-amino-4-methylcoumarins by fI is unaffected by the presence of fH or C3(NH3). The amidolytic activity is inhibited by the synthetic thrombin inhibitor Z-d-Phe-Pro-methoxypropylboroglycinepinanediol ester, consistent with previous reports, and by benzenesulfonyl fluorides such as Pefabloc SC. Suramin inhibits fI directly at concentration of 1 mM. Within a range of metal ions tested, only Cr2+ and Fe3+ were found to inhibit both the proteolytic and amidolytic activity of fI.


Acta Crystallographica Section F-structural Biology and Crystallization Communications | 2011

Structures of the rat complement regulator CrrY

Pietro Roversi; Steven Johnson; Joseph J. E. Caesar; Florence McLean; Kirstin Leath; Stefanos A. Tsiftsoglou; Bryan Paul Morgan; Claire L. Harris; Robert B. Sim; Susan M. Lea

The structure of rat CrrY1–4 determined in two distinct crystal forms shows a pronounced bend at the interface between domains 3 and 4.


Biochemical Pharmacology | 2005

Eukaryotic arylamine N-acetyltransferase: Investigation of substrate specificity by high-throughput screening

Akane Kawamura; James Graham; Adeel Mushtaq; Stefanos A. Tsiftsoglou; Gregory M. Vath; Patrick E. Hanna; Carston R. Wagner; Edith Sim


Biochemistry | 2005

The catalytically active serine protease domain of human complement factor I.

Stefanos A. Tsiftsoglou; Antony C. Willis; Pengyun Li; Xuehui Chen; Daniel Anthony Mitchell; Zihe Rao; Robert B. Sim


Biochimica et Biophysica Acta | 2006

Human complement factor I glycosylation: structural and functional characterisation of the N-linked oligosaccharides.

Stefanos A. Tsiftsoglou; James N. Arnold; Pietro Roversi; Max Crispin; Catherine M. Radcliffe; Susan M. Lea; Raymond A. Dwek; Pauline M. Rudd; Robert B. Sim


Archive | 2013

SubstratesCofactors for Cleavage of Synthetic Human Complement Factor I Does Not

Stefanos A. Tsiftsoglou; Robert B. Sim


Molecular Immunology | 2011

Structural basis for complement Factor I control and its disease associated sequence polymorphisms

Steven Johnson; Pietro Roversi; Joseph J. E. Caesar; F. McClean; Kirstin Leath; Stefanos A. Tsiftsoglou; Bryan Paul Morgan; Claire L. Harris; Robert B. Sim; Susan M. Lea


Acta Crystallographica Section A | 2011

Structural basis for complement Factor I control and its disease-associated sequence polymorphisms

Pietro Roversi; Steven Johnson; Joseph J. E. Caesar; F. McLean; Kirstin Leath; Stefanos A. Tsiftsoglou; Bryan Paul Morgan; Claire L. Harris; Robert B. Sim; Susan M. Lea


Molecular Immunology | 2008

Complement activation in a mouse model of amyotrophic lateral sclerosis

Isaac M. Chiu; Bela Kosaras; Stefanos A. Tsiftsoglou; Ming Zhang; Timothy Vartanian; Michael C. Carroll

Collaboration


Dive into the Stefanos A. Tsiftsoglou's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge